Development
Maze Therapeutics' MZE829 shows positive phase 2 results in APOL1-mediated kidney disease trial
Maze Therapeutics (Nasdaq: MAZE), based in South San Francisco, reported topline data from its Phase II HORIZON trial of MZE829, an oral APOL1 inhibitor, in...
Dong-A ST Advances CLDN18.2-Targeting ADC DA-3501 Into Phase I/IIa Trial for Gastric Pancreatic Cancer
South Korean pharmaceutical company Dong-A ST has registered a first-in-human Phase I/IIa clinical trial for DA-3501, a Claudin 18.2-targeting antibody-drug...
Pfizer's atirmociclib shows progression-free survival benefit in CDK4/6 inhibitor-resistant breast cancer trial
Pfizer announced topline results from the randomized Phase II FOURLIGHT-1 trial evaluating atirmociclib in breast cancer patients whose disease had...
Mirador Therapeutics Launches Phase 1 Trial of MT-251 Bispecific Antibody Targeting TL1A and IL-23
Mirador Therapeutics has initiated dosing in a Phase 1 MT-251 clinical trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of...
Bayer's finerenone meets primary endpoint in Phase III non-diabetic chronic kidney disease study
Bayer announced that finerenone (KERENDIA) met the primary endpoint of its Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease,...
Pfizer's atirmociclib cuts progression risk by 40% in second-line metastatic breast cancer trial
Pfizer (NYSE: PFE) reported Phase II results for atirmociclib in HR-positive, HER2-negative metastatic breast cancer, with the FOURLIGHT-1 trial meeting its...
Iterion Therapeutics doses first patient with tegavivint in metastatic colorectal cancer Phase I/II trial
Iterion Therapeutics, a Houston-based clinical-stage oncology company, announced that the first patient has been dosed in a Phase I/II clinical trial...
Innovent Biologics advances IBI354 into pivotal first-line HER2-positive breast cancer trial
China-based Innovent Biologics (HKEX: 01801) announced the dosing of the first participant in HeriCare-Breast01, a pivotal Phase III study evaluating...
Inhibikase's IB-001: First-in-Human Phase 1 Trial Targets Chronic Hepatitis B Treatment
A Novel Approach to Chronic Hepatitis B: Inside Inhibikase's First-in-Human IB-001 Trial
Lilly's selpercatinib meets primary endpoint in adjuvant RET fusion-positive lung cancer trial
Eli Lilly announced positive topline results from the Phase III LIBRETTO-432 trial evaluating Retevmo (selpercatinib), a selective RET kinase inhibitor, as...
Kymera Therapeutics Advances KT-579 IRF5 Degrader Into Phase 1 Trial for Autoimmune Disease
Kymera Therapeutics has begun dosing participants in the first-ever clinical study of a drug designed to destroy interferon regulatory factor 5, a...
Response Pharmaceuticals' RDX-002 shows positive phase 2 results for post-GLP-1 obesity weight management
Virginia-based Response Pharmaceuticals announced 36-week Phase 2 data for RDX-002, a gut-restricted inhibitor of intestinal microsomal triglyceride...
Roche's giredestrant advances toward FDA review for ESR1-mutated breast cancer treatment
Roche announced that the US FDA has accepted a New Drug Application for giredestrant, an oral selective oestrogen receptor degrader (SERD), in combination...
IMUNON's IMNN-001 shows 14.7-month survival benefit in advanced ovarian cancer phase II trial
IMUNON, Inc., a clinical-stage biotechnology company based in Lawrenceville, N.J., reported final Phase II data from the OVATION 2 trial evaluating IMNN-001...
Pfizer's talazoparib plus enzalutamide meets Phase III endpoint in metastatic castration-sensitive prostate cancer
Pfizer (NYSE: PFE) announced positive topline results from the Phase III TALAPRO-3 trial evaluating Talzenna (talazoparib) plus Xtandi (enzalutamide) in...
The AllSci Brief
Systematic R&D and deal news. Daily.